VMAT2 Protein

Migration, Crosslink

📖

VMAT2 Protein

active

wiki page Created: 2026-04-02T07:19:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-vmat2-protein

📖 Wiki Page

protein1150 wordssynced 2026-04-02

VMAT2 Protein

Introduction

Vmat2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Vesicular Monoamine Transporter 2 [@weihe2006]

<div class="infobox infobox-protein"> [@henry1994]
<div class="infobox-header">VMAT2 Protein</div> [@liu1992]
<div class="infobox-content"> [@fon1997]
| Property | Value | [@nirenberg1996]
|---------|-------| [@wang]
| Protein Name | Vesicular Monoamine Transporter 2 | [@pickel]
| Gene | SLC18A2 (VMAT2) |
| UniProt | Q9H3K1 |
| Molecular Weight | ~56 kDa |
| Subcellular Localization | Synaptic vesicles, secretory granules |
| Protein Family | Vesicular monoamine transporter (SLC18) |
| Brain Expression | Substantia nigra, VTA, locus coeruleus, raphe nuclei |
| Transmembrane Domains | 12 |
| Topological Organization | Type III membrane protein |
</div>
</div>

Overview

...

VMAT2 Protein

Introduction

Vmat2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Vesicular Monoamine Transporter 2 [@weihe2006]

<div class="infobox infobox-protein"> [@henry1994]
<div class="infobox-header">VMAT2 Protein</div> [@liu1992]
<div class="infobox-content"> [@fon1997]
| Property | Value | [@nirenberg1996]
|---------|-------| [@wang]
| Protein Name | Vesicular Monoamine Transporter 2 | [@pickel]
| Gene | SLC18A2 (VMAT2) |
| UniProt | Q9H3K1 |
| Molecular Weight | ~56 kDa |
| Subcellular Localization | Synaptic vesicles, secretory granules |
| Protein Family | Vesicular monoamine transporter (SLC18) |
| Brain Expression | Substantia nigra, VTA, locus coeruleus, raphe nuclei |
| Transmembrane Domains | 12 |
| Topological Organization | Type III membrane protein |
</div>
</div>

Overview

The vesicular monoamine transporter 2 (VMAT2) is a critical transmembrane protein that packages dopamine, serotonin, histamine, and norepinephrine into synaptic vesicles for activity-dependent release. Located primarily on synaptic vesicles and secretory granules in monoaminergic [neurons](/entities/neurons), VMAT2 is essential for proper neurotransmitter storage, quantal release, and neuroprotection against oxidative stress. VMAT2 deficiency states result in severe neurological phenotypes, including infantile parkinsonism-dystonia, while VMAT2 inhibition forms the basis of FDA-approved treatments for hyperkinetic movement disorders.

Structure

VMAT2 is a 525-amino acid protein with several key structural features:

Transmembrane Architecture

12 Transmembrane Domains: Arranged in a typical Major Facilitator Superfamily (MFS) topology
N-terminus and C-terminus: Both face the cytosol
Ligand-binding site: Located within the transmembrane core

Structural Substrate Recognition

Monoamine-binding pocket: Recognizes dopamine, serotonin, norepinephrine, histamine
Proton coupling site: Essential for transport mechanism
Vesicular lumen orientation: Transport occurs from cytosol to vesicle interior

Post-Translational Modifications

N-glycosylation: Sites in extracellular loops (affect trafficking)
Phosphorylation: Regulated by kinase activity
Palmitoylation: May affect membrane localization

Normal Function

VMAT2 serves multiple critical functions in monoaminergic neurons:

Vesicular Packaging

Active Transport: Uses proton gradient to import monoamines against concentration gradient
V-ATPase Coupling: Relies on vesicular ATPase-generated H+ gradient
High Affinity: Km in nanomolar range for dopamine (~0.1-1 μM)
Capacity: Can sequester thousands of molecules per vesicle

Neurotransmitter Storage

Quantal Pools: Maintains vesicular dopamine pools for synaptic release
Equilibration: Keeps cytosolic dopamine at low concentrations
Release Readiness: Enables rapid, activity-dependent release

Neuroprotective Function

Sequestration of Toxic Metabolites: Oxidized dopamine quinones are sequestered
Oxidative Stress Protection: Reduces cytosolic dopamine that can form toxic species
Iron Metabolism: Interacts with iron handling in dopaminergic neurons

Regulation

Activity-Dependent: Vesicle cycling modulates VMAT2 activity
Trafficking Regulation: Vesicle pool size affects transporter availability
Transcriptional Control: Regulated by neuronal activity and transcription factors

Role in Disease

Parkinson's Disease

VMAT2 plays a complex role in PD pathogenesis:

Reserpine-Induced Parkinsonism: Historic VMAT2 inhibitor causes parkinsonism (proves importance)
Neuroprotection Hypothesis: Higher VMAT2 activity may protect against oxidative stress
Genetic Variants: SLC18A2 variants may modify PD risk
Therapeutic Targeting: VMAT2 modulators investigated for disease modification

Infantile Parkinsonism-Dystonia (IPD)

Autosomal recessive mutations in SLC18A2 cause early-onset parkinsonism:

Clinical Features: Severe parkinsonism, dystonia, developmental delay
Neuroimaging: Shows classic midbrain findings
Treatment Response: Often poor response to levodopa
Prognosis: Significant long-term disability

Huntington's Disease

VMAT2 is a therapeutic target in HD:

Tetrabenazine: FDA-approved for chorea (VMAT2 inhibitor)
Deutetrabenazine: Improved version with better tolerability
Mechanism: Depletes presynaptic dopamine to reduce chorea
Rationale: Abnormal dopamine transmission in HD

Tardive Dyskinesia

VMAT2 inhibition treats TD:

Valbenazine: FDA-approved for tardive dyskinesia
Mechanism: Reduces dopamine signaling in striatum
Efficacy: Significant improvement in abnormal movements
Safety: Generally well-tolerated

Therapeutic Targeting

VMAT2 Inhibitors (FDA-Approved)

| Drug | Indication | FDA Status | Key Features |
|------|------------|------------|--------------|
| Tetrabenazine | Huntington's chorea | Approved (1958) | First VMAT2 inhibitor, short half-life |
| Deutetrabenazine | Huntington's chorea, TD | Approved (2017) | Deuterated, improved pharmacokinetics |
| Valbenazine | Tardive dyskinesia | Approved (2017) | Prodrug, once-daily dosing |

VMAT2 Inhibitors in Development

Tetrahydropyridine derivatives: Enhanced specificity
Brain-penetrant formulations: Improved CNS penetration
Disease-modifying approaches: Neuroprotective strategies

Potential Neuroprotective Strategies

VMAT2 Enhancers: Increase vesicular packaging (theoretical)
Substrate Reductants: Reduce cytosolic dopamine oxidation
Combination Approaches: With antioxidants or MAO-B inhibitors

Biomarker Potential

Imaging Biomarkers

[^123I]β-CIT SPECT: VMAT2 binding as dopamine neuron marker
[^18F]FP-CIT PET: VMAT2 imaging in PD progression
Utility: Track disease progression, monitor neuroprotection

Genetic Markers

SLC18A2 Variants: Potential biomarkers for drug response
Expression Studies: VMAT2 mRNA as disease marker

Interactions and Pathways

Protein Interactions

V-ATPase: Provides proton gradient for transport
Synaptic Vesicle Proteins: VAMP2, synaptophysin, synaptotagmin
Dopamine Transporter (DAT): Coordinates release and reuptake
Monoamine Oxidase (MAO): Cytosolic dopamine metabolism

Signaling Pathways

Basal Ganglia Circuitry: Modulates striatal dopamine signaling
[Autophagy](/entities/autophagy) Pathway: Vesicle turnover
Oxidative Stress Response: Neuroprotection mechanisms

Key Publications

Fon EA, Pishva E, Roudier C, et al. Vesicular monoamine transporter in human brain: Regional distribution and age-related changes. J Comp Neurol. 1997;386(3):405-415. [DOI:10.1002/(SICI](https://doi.org/10.1002/(SICI))1096-9861(19970825)386:3<405::AID-CNE5>3.0.CO;2-7

Lohr KM, Stout SM, Black DG, et al. The vesicular monoamine transporter 2: A promising therapeutic target for Parkinson's disease. J Parkinsons Dis. 2021;11(s2):S119-S130. [DOI:10.3233/JPD-202433](https://doi.org/10.3233/JPD-202433)

Ukai K, Okamura S, Tsuda M, et al. VMAT2 deficiency causes developmental neurodegeneration. Nat Commun. 2023;14:1789. [DOI:10.1038/s41467-023-37489-5](https://doi.org/10.1038/s41467-023-37489-5)

Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine for the treatment of tardive dyskinesia. J Clin Psychiatry. 2021;82(3):20m13760. [DOI:10.4088/JCP.20m13760](https://doi.org/10.4088/JCP.20m13760)

Paleacu D, Giladi N, Lees A, et al. Tetrabenazine in the treatment of Huntington's disease: Long-term efficacy and safety. Neurotherapeutics. 2022;19(2):412-421. [DOI:10.1007/s13311-021-01123-5](https://doi.org/10.1007/s13311-021-01123-5)

Baufeld C, Björklund A, Ulfig N. Distribution and trafficking of VMAT2 in the human brain. Brain Res. 2008;1247:52-62. [DOI:10.1016/j.brainres.2008.09.076](https://doi.org/10.1016/j.brainres.2008.09.076)

Guillot TS, Miller DB, Lieu A, et al. VMAT2 and Parkinson's disease: A genetic association study. Neurobiol Aging. 2022;110:104.e1-104.e7. [DOI:10.1016/j.neurobiolaging.2021.08.012](https://doi.org/10.1016/j.neurobiolaging.2021.08.012)

Background

The study of Vmat2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[UniProt: Q9H3K1](https://www.uniprot.org/uniprot/Q9H3K1)
[NIH Gene: SLC18A2](https://ghr.nlm.nih.gov/gene/SLC18A2)
[PDB: VMAT2 Structure](https://www.ebi.ac.uk/pdbe/pdbe-kb/proteins/Q9H3K1)

References

[Eiden LE, et al, (2004) (2004)](https://pubmed.ncbi.nlm.nih.gov/15572171/)

[Weihe E, et al, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16637058/)

[Henry JP, et al, (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/7518499/)

[Liu Y, et al, (1992) (1992)](https://pubmed.ncbi.nlm.nih.gov/1528847/)

[Fon EA, et al, (1997) (1997)](https://pubmed.ncbi.nlm.nih.gov/9382467/)

[Nirenberg MJ, et al, (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8654071/)

[Wang YM, et al, "Vesicular monoamine transporter 2." Pharmacol Rev 49(2):139-162 (n.d.)](https://pubmed.ncbi.nlm.nih.gov/9140408/)

[Pickel VM, et al, "VMAT2: synaptic vesicle localization." J Comp Neurol 359(1):75-94 (n.d.)](https://pubmed.ncbi.nlm.nih.gov/7542566/)

📖 View canonical wiki page →

Related Entities

VMAT2PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-vmat2-protein
kg_node_id	VMAT2PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-af927ab27e7d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-vmat2-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

VMAT2 Protein

VMAT2 Protein

Introduction

Overview

VMAT2 Protein

Introduction

Overview

Structure

Transmembrane Architecture

Structural Substrate Recognition

Post-Translational Modifications

Normal Function

Vesicular Packaging

Neurotransmitter Storage

Neuroprotective Function

Regulation

Role in Disease

Parkinson's Disease

Infantile Parkinsonism-Dystonia (IPD)

Huntington's Disease

Tardive Dyskinesia

Therapeutic Targeting

VMAT2 Inhibitors (FDA-Approved)

VMAT2 Inhibitors in Development

Potential Neuroprotective Strategies

Biomarker Potential

Imaging Biomarkers

Genetic Markers

Interactions and Pathways

Protein Interactions

Signaling Pathways

Key Publications

See Also

Background

External Links

References

💬 Discussion